NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Syndax Pharmaceuticals (SNDX) Is Up 26.1% After FDA Priority Review for Revuforj and Revenue Surge

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Falls Deeper into Losses and Seeks $250M—Is Its Funding Model Sustainable?

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...